YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[US Food and Drug Administration (FDA)] The U.S. FDA has approved Eli Lilly’s (LLY [https://seekingalpha.com/symbol/LLY]) bid to market its eczema therapy Ebglyss as a single maintenance dose administered every eight weeks, allowing patien…
* Almirall, S.A. press release [https://backend.almirall.com/sites/default/files/2026-05/EN-Financial_Results_Business_Update_Q1-2026-vFinal.pdf] (LBTSF [https://seekingalpha.com/symbol/LBTSF]): Q1 EBITDA of €67.5M. * Net Sales of €291.0M.…
The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as…
Shanghai EpimAb Biotherapeutics Co., Ltd. SHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of novel multispecific antibodies, today announced the…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Almirall overview and recent share performance Almirall (BME:ALM) has drawn investor attention after recent trading, with th…
China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline hydrochloride) for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. Sarec…
Ipsen Pharma Ipsen Board of Directors Peter GuenterIpsen announced the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026.·GlobeNewswire Inc. PARIS, FRANCE, 29 January 2026 - Ipsen (Euronext: IPN; ADR: IPSE…
Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease mechanisms including IL-13 and therefore makes targeting IL-13 with lebrikizumab a potentially promising therapeutic opti…
Pipeline advances in 2026 span a range of dermatology disease areas, including atopic dermatitis, hidradenitis suppurativa, and alopecia areata, with 3 ongoing PoC/Phase II clinical studies* and 3 additional studies to be initiated in 2026…
Almirall (BME:ALM) shares edged higher today, gaining just under 2%. This move has caught the attention of investors, who are keen to understand what might be driving sentiment for the Spanish pharmaceutical company. See our latest analysi…
This article first appeared on GuruFocus. Net Sales Growth: Nearly 13% year-on-year increase in the first nine months of 2025. Gross Margin: Moderated to 64.9% of sales, reflecting ongoing pressure related to illumetric royalties. EBITDA:…
Almirall continues its sustained growth trajectory in 9M 2025 - delivering 12.8% net sales growth, strong dermatology performance, solid commercial execution in Europe, and further pipeline progress Sustained strong growth momentum with 12…
Almirall (BME:ALM) shares have quietly advanced this month, gaining 7% over the past four weeks. Investors might be paying closer attention to the company’s fundamentals as the company shows steady annual revenue and net income growth. See…
If you are wondering whether now is the right moment to make a move on Almirall, you are definitely not alone. Over the last year, Almirall’s stock has turned quite a few heads, climbing a remarkable 35.7%. The gains stretch even further,…
Absci Corporation Almirall selects second target in AI Drug Creation collaboration Expanded collaboration builds on Absci’s successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almir…
Almirall Continues to Deliver on its Long-Term Growth Strategy with Net Sales Growth of 12.7% in H1 2025, Driven by a Strong European Dermatology Business and Increasing Biologics Sales Solid growth trajectory maintained: H1 net sales incr…
As the European markets experience mixed returns, with the STOXX Europe 600 Index remaining roughly flat and major indices showing varied performance, investors are keeping a close eye on economic indicators such as inflation and labor mar…
As global markets react positively to the recent U.S.-China tariff suspension, with major indices such as the Nasdaq Composite and S&P 500 showing significant gains, investors are keenly observing how these developments might influence bro…
Net Sales Growth: 15% increase year on year, with a 10% growth excluding out-licensing impact. Ilumetri Sales: EUR 55 million in Q1 2025, up 13% year on year. EMIs Sales: EUR 19.4 million in Q1 2025, a 52% increase quarter on quarter. Gros…
Almirall HQ in Barcelona Almirall delivers a strong start to 2025: growing Q1 overall sales by 15%, and 23.4% in its European Dermatology business YoY, aligned with the company’s sustained growth trajectory Continued strong growth trajecto…
As European markets show signs of recovery, bolstered by the European Central Bank's interest rate cuts and a delay in higher tariffs, investors are keenly observing opportunities that may arise from these developments. In such an environm…